Theorem Clinical Research Adds Two Top-Level Executives to a Growing Team

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Alison Taber and Jeff Wiley, professionals with years of clinical research experience, are the latest executives to join Theorem Clinical Research as the company continues to expand to meet the growing demand for its clinical trial management services.

Taber will take on responsibilities as vice president of global data management. She comes to Theorem from INC Research where she had been executive director of strategic alliance management. Her 20-year career includes senior roles at major contract research organizations including Quintiles and PPD, and as chief operating officer of Copernicus Group IRB. In her new role at Theorem, she will be responsible for Theorem's global data management services for functional service provision, special projects and full-service studies.

Wiley brings 13 years of clinical research experience, including eight years in clinical operations management to his new role at Theorem. As senior director of clinical operations, Wiley will have responsibility for clinical operations in the E.U. and the Americas. He was previously senior director of clinical operations for PRA, where he had held positions of increasing authority and responsibility in the company's Lenexa, Kan., and Charlottesville, Va. facilities.

"To address our growth, we are looking for bright, capable professionals who have the right experience and are ready to take on more responsibilities," said Theorem President and CEO John Potthoff. "Alison and Jeff are just the kind of people we want to recruit to Theorem and I am confident they will both be assets to the company."

About Theorem Clinical Research

Theorem Clinical Research Inc. is a leading midsized provider of comprehensive clinical research and development services with offices in more than 30 countries and a customer base comprised of some of the world's top pharmaceutical, biotech and medical device companies. As a forerunner in medical device and drug-device combination trials with notable capabilities in pharmaceuticals and biologics, Theorem offers deep expertise in a broad range of therapeutic areas and in all phases of development. With some of the industry's top scientists and most advanced clinical analytics capabilities, Theorem ensures smooth-running, successful trials. For the full-service, right-size global research partner, don't think twice. THINK THEOREM.

Contacts

Theorem Clinical Research
Cindy Jacobus, 1-484-679-2400
[email protected]

Suggested Articles

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.

The phase 2/3 clinical trial linked REGN-COV2 to a 57% decline in medical visits associated with COVID-19 in the 29 days after treatment.

Drug companies often face steep challenges when entering new markets for the first time. LianBio is here to help.